Prior to 2016, the product sold under the name VSL#3® contained the De Simone Formulation (DSF), a formulation that had been studied and found efficacious for managing inflammatory bowel diseases. In a pivotal turn of events, the product marketed as VSL#3® since June 2016 no longer contain DSF. These facts have been confirmed by U.S. Federal Court rulings, which required the U.S. distributors of VSL#3 to pay $18 million in damages. These rulings are final and no longer subject to any right of appeal. Given that the product sold as VSL#3® is identical in both the U.S. and the EU, the weight of this ruling is not restricted to the U.S. but has global implications.
Given the ethical responsibility of ECCO to provide the most accurate and up-to-date information for the benefit of patients and healthcare providers, it is imperative to clarify that the VSL#3 references in the ECCO Guidelines 2017 exclusively endorse DSF, not VSL#3, supported by scientific evidence. The organization has the obligation to ensure that practitioners and patients have access to the most current, evidence-based information. Please take note of the ECCO's Official Statement:
"Until 2016, the De Simone Formulation (DSF) was sold as VSL#3® and had established its efficacy in inflammatory bowel diseases. After 2016, the VSL#3® product no longer contains DSF. Accordingly, the VSL#3 references in the ECCO Guidelines 2017 exclusively endorse DSF supported by scientific evidence."
With the publication of the 2022 Impact Factor of 8.0 we now see that the Journal is increasing its impact because our articles are being cited even more frequently than before. With its 2022 Impact Factor, the Journal of Crohn's and Colitis (JCC) is one of the top journals in the gastroenterology and hepatology field. Discover which recently published articles have been making an impact by clicking here. JCC continually strives to support the IBD Community through publication of the best original research, ECCO Guidelines and other articles. JCC is appreciated as a top venue by authors in which to publish their work.
The increasing impact of the Journal of Crohn's and Colitis is due to the ongoing support of authors and readers, but also reflects the significant advances being made at the moment in most aspects of IBD research and treatment. Let us hope that the increased Impact Factor of our Journal is paralleled by even better outcomes for patients suffering from IBD all over the world in the near future.
The JCC Editor-in-Chief Laurence Egan and the entire Editorial Team thank all ECCO Members, JCC authors, reviewers and readers for their support of JCC.
The Journal of Crohn's and Colitis is the official journal of the European Crohn's and Colitis Organisation (ECCO) and is concerned with the dissemination of knowledge on clinical, basic science and innovative methods related to Inflammatory Bowel Diseases (IBD).
The journal publishes Original articles, Review articles, Editorials, ECCO Papers, Viewpoints, Short reports, Abstracts and Letters to the Editor. JCC is being published every month (12 issues per year) and covers the knowledge and science related to Inflammatory Bowel Diseases: The aims are to update, innovate and challenge.
JCC is defined as an “International Journal”. Although it is the official journal of ECCO, it is open to everyone in the world interested and working in Inflammatory Bowel Diseases.
In 2010, JCC was accepted for MedLine citation, which motivates us – as ECCO – even more to work on the quality and exposure of our journal.
Advertising and Corporate Services:
Advertising, reprints, peer-reviewed supplements are services available via our publisher Oxford University Press (OUP).